Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line treatment for metastatic kidney cancer
Treatment of advanced (metastatic) kidney cancer has improved considerably over [...]
UK regulators approve injectable form of nivolumab for solid tumours
The Medicines and Healthcare products Regulatory Agency (MHRA) in the [...]
Immunotherapy for the treatment of non-clear cell kidney cancer
There are several types of kidney cancer, the most common [...]
Europe has approved subcutaneous nivolumab for solid tumours
The Committee for Medicinal Products for Human Use (CHMP) of [...]
FDA approves injectable form of nivolumab
Just after Christmas, the US Food and Drug Administration (FDA) [...]
Promising new immunotherapy combination for advanced kidney cancer
The first results from a phase 2 study (FRACTION-RCC) looking [...]
How to manage side effects to cabozantinib and nivolumab
This article gives some good advice about how to manage [...]
Intermittent immunotherapy in patients with metastatic kidney cancer
The combination of ipilimumab/nivolumab is approved for patients as a [...]
Perioperative nivolumab in intermediate/high risk kidney cancer patients
The standard of care for patients with intermediate/high risk kidney [...]
